A Relative Bioavailability Study of Vepdegestrant Tablets in Healthy Adult Participants
Authors:
- 29 June 2026
- journal article
- research article
- Published by Springer Nature in European Journal of Drug Metabolism and Pharmacokinetics
- Vol. 51 (5) , 1-9
Abstract
Background and Objective Vepdegestrant is a selective, oral PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader in development for the treatment of ER-positive/human epidermal growth factor receptor 2-negative advanced breast cancer. The current study was conducted to estimate the relative bioavailability of single 200-mg doses of commercially representative vepdegestrant tablets (2 × 100-mg strength and 1 × 200-mg strength) compared with a single 200-mg dose of the pivotal phase 3 vepdegestrant tablets (2 × 100-mg strength). Methods This phase 1, randomized, open-label, three-period, three-treatment, six-sequence, crossover, single-dose study in healthy adults was conducted according to bioequivalence standards. Participants were to receive three vepdegestrant treatments over three treatment periods. Serial pharmacokinetic blood samples were collected up to 168 h after vepdegestrant administration in each period. Results Fifty-two participants were enrolled and treated in the study. Following administration, vepdegestrant plasma concentration–time curves for both commercially representative tablets (test) and the pivotal phase 3 tablets (reference) were nearly superimposable. The 90% confidence intervals for the test/reference adjusted geometric means ratios of vepdegestrant area under the plasma concentration–time curve from time zero to infinity and maximum plasma concentration for both commercially representative tablets relative to the pivotal phase 3 tablets fell completely within prespecified standard bioequivalence limits (80.00–125.00%). Adverse event rates were similar across tablet formulations. Conclusions Commercially representative vepdegestrant tablets demonstrated bioequivalence with the pivotal phase 3 vepdegestrant tablets; all tablet formulations of vepdegestrant 200 mg were well tolerated. Clinical Trial Registration NCT06347861; registered March 29, 2024.Keywords
Funding Information
- Pfizer
- Arvinas Estrogen Receptor, Inc
This publication has 10 references indexed in Scilit:
- Effect of carbamazepine on the pharmacokinetics of vepdegestrant, a PROteolysis TArgeting Chimera estrogen receptor degrader, in healthy adultsBritish Journal of Clinical Pharmacology, 2026
- The Effect of Itraconazole on the Pharmacokinetics of Vepdegestrant, a PROteolysis TArgeting Chimera Estrogen Receptor Degrader, in Healthy Adult ParticipantsClinical Therapeutics, 2026
- Effect of vepdegestrant, a PROTAC oestrogen receptor degrader, on dabigatran and rosuvastatin pharmacokinetics in healthy participantsBritish Journal of Clinical Pharmacology, 2025
- Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast CancerNew England Journal of Medicine, 2025
- Abstract P4-08-13: Evaluating CYP3A4-Mediated Drug Interaction Risks for Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, in Combination With Cyclin-Dependent Kinase (CDK)4/6 Inhibitors and EverolimusClinical Cancer Research, 2025
- Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer ModelsClinical Cancer Research, 2024
- Protein degraders enter the clinic — a new approach to cancer therapyNature Reviews Clinical Oncology, 2023
- PROTAC targeted protein degraders: the past is prologueNature Reviews Drug Discovery, 2022
- PROTACs: An Emerging Therapeutic Modality in Precision MedicineCell Chemical Biology, 2020
- Recognition of the polyubiquitin proteolytic signalThe EMBO Journal, 2000